Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 10/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984966 | 0.90 | METAP2 (0.58) | METAP2AAK1TDP1KMT2APOLB | |
| SCHEMBL12022123 | 0.88 | METAP2 (0.55) | METAP2AAK1TDP1KMT2APOLB | |
| SCHEMBL23341558 | 0.86 | METAP2 (0.54) | METAP2AAK1TDP1KMT2APOLB | |
| SCHEMBL7359207 | 0.85 | METAP2 (0.72) | METAP2AAK1TDP1METAP1 | |
| Hydrochloric Acid SCHEMBL7357125 | 0.84 | METAP2 (0.71) | METAP2AAK1TDP1METAP1 | |
| SCHEMBL16176059 | 0.81 | METAP2 (0.57) | METAP2POLBMETAP1 | |
| SCHEMBL19350499 | 0.79 | EPHX2 (0.54) | METAP2KMT2APOLBMETAP1 | |
| SCHEMBL17880860 | 0.77 | METAP2 (0.47) | METAP2AAK1KMT2APOLBMETAP1 | |
| SCHEMBL14985006 | 0.77 | METAP2 (0.47) | METAP2AAK1KMT2APOLBMETAP1 | |
| SCHEMBL16176111 | 0.77 | TAS1R3 (0.48) | METAP2KMT2AMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-9730955-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885AAK1 4036/4885TDP1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.